PER percheron therapeutics limited

Ann: Notices received under s203D and s249D of Corporations Act, page-47

  1. 4,275 Posts.
    lightbulb Created with Sketch. 2047
    That is utter nonesense gassy
    If MRI is set up as a biomarker as a secondry endpoint then fact it is accepted by the FDA
    infact the FDA are promoting new trials to engage further with MRI in clinical trials

    and personally i believe it is what got Duvyzat over the line with the FDA when they recieved Marketing approval

    UF researchers led by Vandenborne, the director of neuromuscular dystrophy research program ImagingNMD, have pioneered the use of MR biomarkers to capture highly accurate and noninvasive measures of muscle changes in children with Duchenne. Using MR measures in studies like these overcomes the limitations of traditional methods of determining study outcomes, such as measuring a child’s walking speed or other timed functional tests, Vandenborne said.


    https://ufhealth.org/news/2024/uf-t...wly-approved-duchenne-muscular-dystrophy-drug

    i wouldnt be surprised in the future if MRI does ot become the standard in the likes of DMD trials as it says

    Using MR measures in studies like these overcomes the limitations of traditional methods of determining study outcomes, such as measuring a child’s walking speed or other timed functional tests, Vandenborne said.

    and yes it is very much accepted by the FDA and they are promoting so

    The only reason that our data was unacceptable in the 2A is because it was not set up before hand pre trial to be used specifically as a biomarker

    there is a difference if it is set up in the trial investigation then it can and has been used as a biomarker as i said as Duvyzat have proven their results were backed in by this process and showed clinical change

    say no more
    Last edited by samfiodiving: 07/01/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.0¢
Change
0.000(0.00%)
Mkt cap ! $10.87M
Open High Low Value Volume
1.0¢ 1.0¢ 1.0¢ $35.01K 3.501M

Buyers (Bids)

No. Vol. Price($)
1 4329046 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 3323423 6
View Market Depth
Last trade - 15.35pm 23/06/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.